Non Hodgkin Lymphoma Clinical Trial
A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma
Summary
This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma in Part 2, as well as participants with lymphoma that has come back after treatment (called "relapsed") or did not respond to treatment (called "refractory"), in Part 1. Follicular lymphoma is a type of non-Hodgkin lymphoma or NHL.
This study is made up of 3 parts: Part 1A (non-randomized), Part 1B and Part 2 (randomized - controlled). The aim of Part 1A and Part 1B of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy to be used in Part 2 of the study.
The aim of Part 2 of the study is to assess how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy (the current standard-of-care for NHL). Standard-of-care means the usual medication expected and used when receiving treatment for a condition.
The study is looking at several other research questions, including:
What side effects may happen from taking the study drug
How much study drug is in your blood at different times
Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
The impact from the study drug on your quality-of-life and ability to complete routine daily activities
Eligibility Criteria
Key Inclusion Criteria:
Have diagnosis of cluster of differentiation 20 positive (CD20+) FL grade 1-3a, stage II bulky or stage III / IV
For Part 1A: previously untreated participants who have Follicular Lymphoma International Prognostic Index (FLIPI)-1 score of 3 to 5, or R/R FL who have not received R-CHOP or R-CVP.
For Part 1B: previously untreated participants who have FLIPI-1 score of 3 to 5
For Part 2: previously untreated participants who have FLIPI-1 score of 0 to 5
Have measurable disease on cross sectional imaging documented by diagnostic computed tomography [CT], or magnetic resonance imaging [MRI] imaging, as described in the protocol
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Adequate bone marrow and hepatic function.
Key Exclusion Criteria:
Participants with central nervous system lymphoma or leptomeningeal lymphoma
Participants with histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
Participants with Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), grade 3b follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma
Recent major surgery and history or organ transplantation
A malignancy other than NHL unless the participant is adequately and definitively treated and any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 35 Locations for this study
Noblesville Indiana, 46062, United States More Info
Principal Investigator
Lexington Kentucky, 40536, United States More Info
Principal Investigator
Grand Rapids Michigan, 49503, United States More Info
Principal Investigator
Westbury New York, 11590, United States More Info
Principal Investigator
Houston Texas, 77030, United States More Info
Principal Investigator
Ogden Utah, 84405, United States More Info
Principal Investigator
Waukesha Wisconsin, 53188, United States More Info
Principal Investigator
Ghent East Flanders, 9000, Belgium More Info
Principal Investigator
Sint-Niklaas East Flanders, 9100, Belgium More Info
Principal Investigator
Kortrijk West Flanders, 8500, Belgium More Info
Principal Investigator
Brussels , 1000, Belgium More Info
Principal Investigator
Santiago Santiago Metropolitan Region, 75802, Chile More Info
Principal Investigator
Santiago , 76201, Chile More Info
Principal Investigator
Ravenna Emilia-Romagna, 48121, Italy More Info
Principal Investigator
Meldola Forli-Cesena, 47014, Italy More Info
Principal Investigator
Katowice Silesia, 40-51, Poland More Info
Principal Investigator
Sabadell Barcelona, 08290, Spain More Info
Principal Investigator
Pamplona Navarre, 31008, Spain More Info
Principal Investigator
Madrid , 28027, Spain More Info
Principal Investigator
Madrid , 28031, Spain More Info
Principal Investigator
Madrid , 28034, Spain More Info
Principal Investigator
Madrid , 28223, Spain More Info
Principal Investigator
Salamanca , 37007, Spain More Info
Principal Investigator
Sevilla , 41013, Spain More Info
Principal Investigator
Terrassa , 08221, Spain More Info
Principal Investigator
Bangkok , 10330, Thailand More Info
Principal Investigator
Khon Kaen , 40000, Thailand More Info
Principal Investigator
Adapazari Sakarya, 54290, Turkey More Info
Principal Investigator
Ankara , 06200, Turkey More Info
Principal Investigator
Tekirdag , 59100, Turkey More Info
Principal Investigator
How clear is this clinincal trial information?